Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD/HP vs HD): study protocol.

ABSTRACT:

Introduction

Haemodialysis (HD) is the cornerstone treatment for patients with end-stage renal disease (ESRD). However, highly protein bound or large molecular weight uremic toxins such as phenolic and indolic compounds and homocysteine, which are associated with adverse outcomes such as cardiovascular disease of patients with ESRD, are difficult to remove via HD but can be effectively eliminates by haemoperfusion (HP). The proposed trial (referred to as HD/HP vs HD below) is a randomised, open-label, multicentre trial comparing HD plus HP versus HD alone in adult patients with ESRD. The primary endpoint measure is all-cause mortality.

Methods and analysis

We plan to enrol 1364 maintenance HD patients from 11 medical centres in Shanghai. Participants will be randomised to re

SUBMITTER: Lu W 

PROVIDER: S-EPMC6067402 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature